Gadoxetate disodium

Drug Profile

Gadoxetate disodium

Alternative Names: EOB Primovist; Eovist; gadolinium EOB DTPA; gadoxetic acid; Gd-EOB-DTPA; Primovist; ZK 139834

Latest Information Update: 04 Nov 2015

Price : $50

At a glance

  • Originator Massachusetts General Hospital
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver disorders

Most Recent Events

  • 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
  • 06 Feb 2014 Bayer HealthCare Pharmaceuticals plans a phase III trial for Liver disorders (diagnosis, in infants) in USA (NCT02084628)
  • 01 Dec 2013 Launched for Liver disorders (diagnosis) in Australia, Austria, Belgium, Canada, China, Czech Republic, Finland, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Portugal, Russia, Spain, Switzerland and Turkey (IV) before December 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top